Video

Dr. Sankhala on the TRC105/Pazopanib Combination in Angiosarcoma

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

Pazopanib is approved for the treatment of advanced angiosarcoma, but evidence of activity has been modest, with a median progression-free survival (PFS) of 3 months, and a median overall survival (OS) of 9.9 months, according to a recent study in which none of the patients achieved complete responses.

Endoglin is a surface receptor expressed on activated endothelium, including tumor vasculature, and it is also expressed on angiosarcoma tumor tissue and could be a potential driver of this endothelial malignancy. The receptor may mediate resistance to pazopanib. A phase Ib/IIa study of the endoglin antibody TRC105 combined with pazopanib in patients with advanced soft tissue sarcoma was previously reported at the 2016 ASCO meeting. The current results demonstrate this combination’s activity in an expansion cohort of patients with angiosarcoma.

In this expansion cohort, the combination treatment was both active and well tolerated, and it led to durable complete responses. A global phase III study of pazopanib with or without TRC105 is now planned.

Related Videos
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD